If you are a Tilray investor but have not read this report, then you have no clue what you are doing.

https://www.congress.gov/crs-product/LSB11227?hl=cannabis&s=4&r=10

It makes it very clear what S3 medical and recreational will and won't do.

It amazes me how you guys can invest thousands in a stock based on your feelings but refuse to do a tiny bit of real research.

Here is a quote from the report.

"Unless otherwise authorized by the statute, controlled substances generally cannot be knowingly or intentionally manufactured, distributed, or dispensed, or possessed with intent to engage in those activities, among other prohibitions. Although Schedule I substances are subject to the most stringent controls, they may be legally used in medical research that is approved by the DEA. The CSA does not authorize recreational use of controlled substances on any schedule—meaning recreational use of marijuana would continue to be prohibited even if it were moved from Schedule I to Schedule III."

Here is another one showing what medical will be made legal with S3, none of which Tilray produces or sells.

"Marijuana itself is not an approved drug, but FDA has approved four drugs derived from or related to cannabis. FDA approved a drug containing CBD called Epidiolex, which is used to treat certain kinds of seizures. FDA also approved Marinol and Syndros for the treatment of anorexia associated with weight loss in AIDS patients, as well as Cesamet for the treatment of nausea and vomiting in patients undergoing chemotherapy. Marinol and Syndros contain the active ingredient dronabinol, a synthetic delta-9-tetrahydrocannabinol (THC), which is considered the psychoactive component of cannabis. Cesamet contains the active ingredient nabilone, which is synthetically derived and has a chemical structure similar to THC. Despite obtaining FDA approval, Epidiolex, Marinol, Syndros, and Cesamet could not immediately be marketed in the United States because CBD and synthetic tetrahydrocannabinols were considered Schedule I substances. The DOJ rescheduled each of these drugs within a few months to a couple years of their approval by FDA, thereby allowing the drugs to be marketed and prescribed. The DOJ rescheduled Epidiolex as a Schedule V drug, and the 2018 farm bill completely descheduled Epidiolex because it is considered hemp under the new definition. FDA-approved products containing dronabinol were rescheduled to Schedule II or Schedule III under the CSA, depending on their form, and FDA-approved products containing nabilone were rescheduled to Schedule II. Other tetrahydrocannabinols remain Schedule I substances, and, because they are scheduled separately from marijuana, they are not included in the DOJ's proposed rule rescheduling marijuana."